FAS and neoplasm: We observed that FAS mRNA expression was correlated with the sensitivity of tumor cells to erlotinib (R^2=0.1; p=0.015; RC=0.32) (Figure 7C) and carbozantinib (R^2=0.068; p=0.047; RC=0.28) (Figure 7D), but not related with vemurafenib, dabrafenib, crizotinib and afatinib (Figure 7A,B,E,F).